Physician profile
Douglas Thom
NPI 1164439410
$942.45
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $141 · 2021: $188 · 2022: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.82 | 2019-2022 | |
| Daiichi Sankyo INC. | $139.62 | 2019-2022 | |
| Amgen INC. | $63.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $62.12 | 2019-2020 | |
| Astellas Pharma US INC | $56.64 | 2019-2021 | |
| Myovant Sciences INC. | $52.08 | 2021-2022 | |
| Organon LLC | $45.18 | 2022 | |
| Pfizer INC. | $44.03 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $42.21 | 2022 | |
| Urovant Sciences INC | $34.66 | 2022 | |
| Lupin INC. | $30.10 | 2019 | |
| Aspira Women'S Health INC | $24.69 | 2022 | |
| Davol INC. | $22.84 | 2022 | |
| Allergan, INC. | $20.92 | 2019 | |
| Duchesnay USA Incorporated | $20.52 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $18.27 | 2021 | |
| Minerva Surgical, INC | $14.62 | 2019 | |
| Hologic Sales and Service, LLC | $14.19 | 2019 | |
| Bard Access Systems, INC. | $13.57 | 2019 | |
| Therapeuticsmd, INC. | $11.42 | 2020 | |
| Covidien LP | $11.06 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Thom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.